Page last updated: 2024-09-05

erlotinib hydrochloride and Prostatic Neoplasms

erlotinib hydrochloride has been researched along with Prostatic Neoplasms in 17 studies

Research

Studies (17)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	11 (64.71)	29.6817
2010's	4 (23.53)	24.3611
2020's	2 (11.76)	2.80

Authors

Authors	Studies
Rajput, M; Singh, N; Singh, R; Singh, RP	1
Bhat, TA; Dheeraj, A; Nambiar, DK; Singh, RP; Singh, SP; Yim, DS	1
Bollu, LR; Gao, G; Huang, WC; Hung, MC; Ren, J; Su, F; Weihua, Z; Xu, L	1
Donnini, S; Finetti, F; Giachetti, A; Hanaka, H; Radmark, O; Santi, R; Terzuoli, E; Villari, D; Ziche, M	1
Bearss, D; Cooke, LS; Croce, KD; Mahadevan, D; Qi, W; Riley, C; Saldanha, JW; Stejskal, A	1
Biordi, L; D'Ascenzo, S; Dolo, V; Festuccia, C; Ficorella, C; Gravina, GL; Ricevuto, E; Tombolini, V	1
Bitran, JD; Galvez, A; Kelby, SK; Lestingi, TM; Nabhan, C; Newman, S; Tolzien, K; Tsarwhas, D	1
Kink, JA; Raines, RT; Rutkoski, TJ; Schilling, CI; Strong, LE	1
Carrión-Salip, D; De Llorens, R; Massaguer, A; Menendez, JA; Oliveras, G; Pandiella, A; Panosa, C; Puig, T	1
Lorusso, PM	1
Armstrong, EA; Benavente, S; Chinnaiyan, P; Harari, PM; Huang, S	1
Armstrong, E; Chinnaiyan, AM; Chinnaiyan, P; Harari, PM; Huang, S; Tomlins, SA; Vallabhaneni, G; Varambally, S	1
Ciccolini, J; Ferrero, JM; Fischel, JL; Formento, P; Milano, G	1
Lupu, R; Menendez, JA	1
Agus, DB; Castellanos, O; Green, E; Gross, M; Higano, C; Nguyen, K; Pantuck, A	1
Bologna, M; Dolo, V; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C	1
Bagattini, S; Bladou, F; Brunelle, S; Esterni, B; Gonçalves, A; Gravis, G; Marcy, M; Salem, N; Viens, P; Walz, J	1

Reviews

1 review(s) available for erlotinib hydrochloride and Prostatic Neoplasms

Article	Year
Phase I studies of ZD1839 in patients with common solid tumors. Seminars in oncology, 2003, Volume: 30, Issue:1 Suppl 1 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines	2003

Article

Year

Phase I studies of ZD1839 in patients with common solid tumors.

Seminars in oncology, 2003, Volume: 30, Issue:1 Suppl 1

Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines

2003

Trials

3 trial(s) available for erlotinib hydrochloride and Prostatic Neoplasms

Article	Year
Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial. Urology, 2009, Volume: 74, Issue:3 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Middle Aged; Prostatic Neoplasms; Quinazolines	2009
A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC cancer, 2007, Jul-27, Volume: 7 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Erlotinib Hydrochloride; Humans; Male; Prostatic Neoplasms; Quality of Life; Quinazolines; Survival Rate; Taxoids	2007
Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:9 Topics: Adenocarcinoma; Administration, Oral; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Probability; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome	2008

Other Studies

13 other study(ies) available for erlotinib hydrochloride and Prostatic Neoplasms

Article	Year
EGFR-mediated Rad51 expression potentiates intrinsic resistance in prostate cancer via EMT and DNA repair pathways. Life sciences, 2021, Dec-01, Volume: 286 Topics: Chromones; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Morpholines; Prostatic Neoplasms; Rad51 Recombinase	2021
Decursin inhibits EGFR-ERK1/2 signaling axis in advanced human prostate carcinoma cells. The Prostate, 2023, Volume: 83, Issue:6 Topics: Carcinoma; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Ligands; Male; MAP Kinase Signaling System; Phosphorylation; Prostate; Prostatic Neoplasms	2023
EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors. The Prostate, 2013, Volume: 73, Issue:13 Topics: Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Male; Phosphorylation; Prostate; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Quinazolines; Sodium-Glucose Transporter 1	2013
mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity. Endocrine-related cancer, 2015, Volume: 22, Issue:4 Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Survival; Dinoprostone; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gene Silencing; Human Umbilical Vein Endothelial Cells; Humans; Integrin alpha6; Intramolecular Oxidoreductases; Lung Neoplasms; Male; Mice, Nude; Prostaglandin-E Synthases; Prostatic Neoplasms	2015
MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC cancer, 2009, May-11, Volume: 9 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Mice; Mice, SCID; Multigene Family; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Prostatic Neoplasms; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Thiourea	2009
Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro. The Prostate, 2009, Oct-01, Volume: 69, Issue:14 Topics: Apoptosis; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Receptors, Androgen; RNA, Small Interfering; Signal Transduction	2009
Antitumor activity of ribonuclease multimers created by site-specific covalent tethering. Bioconjugate chemistry, 2010, Sep-15, Volume: 21, Issue:9 Topics: Animals; Antineoplastic Agents; Cattle; Cell Proliferation; Enzyme Inhibitors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Prostatic Neoplasms; Protein Binding; Quinazolines; Ribonuclease, Pancreatic; Sulfhydryl Compounds; Tumor Cells, Cultured	2010
Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. International journal of oncology, 2012, Volume: 41, Issue:3 Topics: Androgens; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Betacellulin; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Male; Neuregulin-1; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Messenger	2012
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer research, 2004, Aug-01, Volume: 64, Issue:15 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mitogen-Activated Protein Kinases; Phosphorylation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured	2004
Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer research, 2005, Apr-15, Volume: 65, Issue:8 Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; DNA-Binding Proteins; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Phosphorylation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Quinazolines; Rad51 Recombinase; Radiation-Sensitizing Agents; Signal Transduction; Xenograft Model Antitumor Assays	2005
Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine. Anti-cancer drugs, 2006, Volume: 17, Issue:7 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Size; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Floxuridine; Humans; Male; Prostatic Neoplasms; Quinazolines; Taxoids; Thymidine Phosphorylase; Thymidylate Synthase	2006
Targeting human epidermal growth factor receptor 2: it is time to kill kinase death human epidermal growth factor receptor 3. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jun-10, Volume: 25, Issue:17 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Prostatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Trastuzumab	2007
Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. The Prostate, 2008, Jun-15, Volume: 68, Issue:9 Topics: Apoptosis; Blotting, Western; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Synergism; Enzyme Activation; Epidermal Growth Factor; Erlotinib Hydrochloride; Flow Cytometry; Humans; Male; Morpholines; Neoplasms, Hormone-Dependent; Phosphorylcholine; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines	2008